Adult dose
Susceptible infections:
Oral: 250-500 mg every 6 hours (manufacturer recommended maximum adult dose: 6 g/day)
I.M., I.V.: 250-500 mg every 6 hours (manufacturer recommended maximum adult dose: 6 g/day)
Dosing recommendations of World Health Organization unless otherwise noted:
Arthritis (septic), methicillin-sensitive Staphylococcus aureus (MSSA) (unlabeled dosing):
I.M., I.V.: 2 g every 6 hours for 2-3 weeks;
Note: Oral therapy of 1 g every 6 hours may be used to complete therapy
if parenteral therapy is discontinued prior to 2-3 week duration
Endocarditis (MSSA) (unlabeled dosing): I.V.:
Native valve: 2 g every 4 hours for 6 weeks; may give with gentamicin for initial 5 days (Choudri, 2000)
Prosthetic valve: 2 g every 4 hours for 6 weeks; give with gentamicin for
2 weeks and rifampin for 6 weeks (Choudri, 2000)
Uncomplicated endocarditis in I.V. drug users: 2 g every 4 hours for 4 weeks and
gentamicin for initial 5 days or 2 g every 4 hours and gentamicin both given for 2 weeks total (Choudri, 2000)
Osteomyelitis (MSSA) (unlabeled dosing): I.M., I.V.: 2 g every 6 hours for 4-6 weeks
(preferred) or for a minimum of 14 days, followed by 1 g every 6 hours orally to complete 4-6 weeks of therapy
Pneumonia (MSSA) (unlabeled dosing): I.M., I.V.: 1-2 g every 6 hours for 10-14 days
Dosing: Pediatric
Note: Dose and duration of therapy can vary depending on infecting organism,
severity of infection, and clinical response of patient. Treat severe staphylococcal infections for at least 14 days;
endocarditis and osteomyelitis require an extended duration of therapy for 4-6 weeks.
The intravenous route should be used for severe infections.
Susceptible infections:
Oral:
Children ≤20 kg: 25-50 mg/kg/day in divided doses every 6 hours
Children >20 kg: Refer to adult dosing.
I.M., I.V.:
Children ≤20 kg: 25-50 mg/kg/day in divided doses every 6 hours; up to 200 mg/kg/day
has been used in some studies for severe infections (Nunn, 2007; St. John, 1981)
Children >20 kg: Refer to adult dosing.
Dosing recommendations of World Health Organization unless otherwise noted:
Arthritis (septic), methicillin-sensitive Staphylococcus aureus (MSSA) (unlabeled dosing):
Children 2 months to 5 years: I.M., I.V.: 25-50 mg/kg (maximum: 2 g)
every 4-6 hours given with ceftriaxone until clinical improvement, followed by oral therapy:
12.5 mg/kg (maximum: 500 mg) every 6 hours; total duration of therapy 2-3 weeks
Children >5 years: I.M., I.V.: 25-50 mg/kg (maximum: 2 g) every 4-6 hours
(maximum daily dose: 12 g/day) until clinical improvement, followed by oral therapy:
25 mg/kg (maximum: 500 mg) every 6 hours; total duration of therapy 2-3 weeks
Endocarditis (MSSA) (unlabeled dosing): I.V.: 50 mg/kg (maximum: 2 g) every 4 hours for 6 weeks;
give with gentamicin for initial 7 days
Osteomyelitis (MSSA) (unlabeled dosing):
Children 2 months to 5 years: I.M., I.V.: 25-50 mg/kg (maximum: 2 g) every 4-6 hours given
with ceftriaxone until clinical improvement, followed by oral therapy: 12.5 mg/kg (maximum: 500 mg)
every 6 hours; total duration of therapy 3-4 weeks
Children >5 years: I.M., I.V.: 25-50 mg/kg (maximum: 2 g) every 4-6 hours (maximum daily dose: 12 g/day)
until clinical improvement, followed by oral therapy: 25 mg/kg (maximum: 500 mg) every 6 hours;
total duration of therapy 3-4 weeks
Pneumonia (MSSA) (unlabeled dosing):
Children 2 months to 5 years: Oral: 25-50 mg/kg (maximum: 2 g) every 6 hours for at least 3 weeks with gentamicin
Children >5 years: I.M., I.V.: 50 mg/kg (maximum: 2 g) every 6 hours for 10-14 days
Cloxacillin Brands
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Cosacillin | Cosmos Limited. | Cosmos Limited | 250mg | 100 | Capsule | per capsule | KES 450.00 |
| Cosacillin | Cosmos Limited. | Cosmos Limited | 125mg | 100ml | Syrup | per 5ML | KES 72.00 |
| Cloxacillin | Elys Chemicals Industries Ltd. | Elys Chemical Industries Ltd. | 250mg | 100 | Capsule | per capsule | KES 175.00 |
| Cloxacillin | Elys Chemicals Industries Ltd. | Elys Chemical Industries Ltd. | 250mg | 1000 | Capsule | per capsule | KES 1,435.00 |
| Cloxacillin | Elys Chemicals Industries Ltd. | Elys Chemical Industries Ltd. | 125mg | 100ml | Syrup | per 5ML | KES 60.00 |
| Cloxacillin | Elys Chemicals Industries Ltd. | Elys Chemical Industries Ltd. | 250mg | 100ml | Syrup | per 5ML | KES 34.00 |
| Cloxapen | Macs Pharmaceuticals | Mac?s Pharmaceuticals Ltd | 250mg | 100 | Capsule | per capsule | KES 160.00 |
| Cloxipen | Macs Pharmaceuticals | Mac?s Pharmaceuticals Ltd | 250mg | 100 | Capsule | per capsule | KES 264.00 |
| Dawaclox | Dawa Limited | Dawa Limited | 125mg | 100ml | Suspension | per 5ML | KES 44.00 |
| Dawaclox | Dawa Limited | Dawa Limited | 250mg | 100 | Capsule | per capsule | KES 220.00 |
| Dawaclox | Dawa Limited | Dawa Limited | 250mg | 1000 | Capsule | per capsule | KES 1,800.00 |
| Dawaclox | Dawa Limited | Dawa Limited | 250mg | 1 | Injection | per vial | KES 18.00 |
| Dawaclox | Dawa Limited | Dawa Limited | 500mg | 1 | Injection | per ampoule | KES 25.00 |
| Kloxy | Laboratory & Allied Ltd. | Laboratory & Allied Ltd | 250mg | 100 | Capsule | per capsule | KES 200.00 |
| Kloxy | Laboratory & Allied Ltd. | Laboratory & Allied Ltd | 250mg | 1000 | Capsule | per capsule | KES 1,600.00 |
| Kloxy | Laboratory & Allied Ltd. | Laboratory & Allied Ltd | 500mg | 1 | Injection | per ml | KES 20.00 |
| Kloxy | Laboratory & Allied Ltd. | Laboratory & Allied Ltd | 125mg | 100ml | Dry Syrup | per 5ML | KES 45.00 |
| Medibenin | Medivet Products Ltd | Medivet Products Ltd. | 250mg | 100 | Capsule | per capsule | KES POR |
| Medibenin | Medivet Products Ltd | Medivet Products Ltd. | 250mg | 1000 | Capsule | per capsule | KES POR |
| Medibenin | Medivet Products Ltd | Medivet Products Ltd. | 125mg | 60ml | Dry Syrup | per 5ML | KES POR |
| Medibenin | Medivet Products Ltd | Medivet Products Ltd. | 125mg | 100ml | Dry Syrup | per 5ML | KES POR |
| Mediclox | Regal Pharmaceuticals | Regal Pharmaceuticals Limited | 125mg | 100ml | Dry Syrup | per 5ML | KES 66.00 |
| Orbenin | GlaxoSmithkline | GlaxoSmithKline | 250mg | 100 | Injection | per vial | KES 4,700.00 |
| Cloxacillin More info | |
|---|---|
| Mode Of Action | Inhibits synthesis of bacterial cell wall, causing cell death, hence bactericidal. required. |
| Drug Indication | Infections due to penicillinase- producing staphylococci. |
| Precautions | Risk of kernicterus in jaundiced neonates when high doses given parenterally. Serious and occasionally fatal immediate hypersensitivity reactions may occur |
| Dosage | Orally: Adult; 500mg six hourly (orally). Children; 25 - 50mg/kg/day. I.M: Adult; - 250mg every 4-6 hours. I.V inj or inf. 500mg every 4-6 hours. Children; 25 - 50mg/kg/day. In severe case doses may be doubled. |
| Pregnancy Category | Category B1 |
| Pregnancy Category Description | Drugs which have been taken by only a small number of pregnant women and women of child-bearing age with no any established rise in the frequency of malformations or other direct or indirect detrimental effects on the foetus having been noted. Studies in animals have not shown evidence of an increased occurrence of foetal damage. |
| Drug Category | DRUGS ACTING ON INFECTIONS |
| Drug Sub-Category | Penicillins |